A Double-blind, Randomized, Multi-Center Study Investigating Efficacy

and Safety of two Different Dosages of Intravenous Human Normal

Immune Globulin (IGIV) 10% in Subjects with Chronic Inflammatory

Demyelinating Polyneuropathy (CIDP)

A Multi-Center Double Blind Placebo Controlled Phase Ii Study Evaluating

The Safety, Pharmacokinetics, Pharmacodynamics And Efficacy Of

Ro7268489, A Monoacylglycerol Lipase Inhibitor, As Add-On Therapy To

Ocrelizumab In Participants With Progressive Forms Of Multiple Sclerosis

A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in

Participants with Early Parkinson’s Disease

A randomized, double-blind, placebo-controlled study to evaluate the

efficacy and safety of remibrutinib in patients with secondary progressive

multiple sclerosis

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of

Fenfluramine Hydrochloride For The Treatment Of Females With Rett

Syndrome

Observational study evaluating subcutaneous LDp/CDp Solution for

Infusion Effectiveness on Sleep Disturbances in Advanced Parkinson’s

Disease

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-

Period Study to Assess the Efficacy and Safety of a New Formulation of

Oral Cladribine Compared with Placebo in Participants with Generalized

Myasthenia Gravis

Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of JX10 in Acute Ischemic Stroke with Late Presentations

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis

Estudio De Prevalencia De Fenotipos De Esclerosis Múltiple En Pacientes Adultos Diagnosticados Con Esclerosis Múltiple En España

First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS).

A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of chronic migraine

A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of episodic migraine

Efficacy and safety of remibrutinib after switching from ocrelizumab in people living with relapsing multiple sclerosis

A Phase IIb Randomized, Double-blind, Placebo-controlled, Multi- Dose Study to Evaluate the Effects of PHENOGENE-1a (Cromolyn) as an Adjuvant Treatment in Subjects with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS).

A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Active Treatment Extension to Assess the Efficacy and Safety of Fosigotifator for the Treatment of Amyotrophic Lateral Sclerosis

A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase

A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early parkinson’s disease

A Phase II, Multicentre, Randomized, Double-blind, Placebo-controlled Sequential Cohort Study to Evaluate the Efficacy and Safety of Two Single Doses of IPN10200 for the Treatment of Blepharospasm in Adults

Un estudio de fase 2 controlado con placebo de VHB937 en la esclerosis lateral amiotrófica (ELA) durante 40 semanas seguido de una extensión abierta

Un estudio de fase 1/2a de escalamiento de dosis para evaluar la seguridad, tolerabilidad, farmacocinética y farmacodinámica de aro-dm1 en sujetos con distrofia miotónica tipo 1 que tienen ≥18 a ≤65 años

Un estudio de grupo paralelo, aleatorizado, doble ciego para comparar Farmacocinética, farmacodinamia, efectos clínicos y seguridad entre ABP 692 y Ocrevus (Ocrelizumab) en sujetos con esclerosis múltiple remitente recurrente.

A phase 2, randomized, observer-blind, placebo-controlled, dose-ranging study of mRNA-1195 intramuscular injection in participants 18 to ≤55 years of age with early MS

A randomized, phase III, open label study to investigate pharmacokinetics, safety, radiological and clinical effects of subcutaneous frexalimab (SAR441344) compared to intravenous frexalimab in adult participants with multiple sclerosis.

An open-label, multi-center, phase 1/2 study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with progressive Multiple Sclerosis (PMS)